Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04296071 · ClinicalTrials.gov registry record

Neutrophil Phenotypic Profiling and Acute Lung Injury in Patients After Cardiopulmonary Bypass (CPB)

A clinical trial of Cardiopulmonary Bypass and Lung Injury, sponsored by Sophia Koutsogiannaki.

Recruiting
Registry status
56
Enrollment target
1
Study location

NCT04296071 is a study of Cardiopulmonary Bypass and Lung Injury that is actively recruiting participants, run by Sophia Koutsogiannaki. The registered enrollment target is 56 participants, below the 738-participant average among 9 other Cardiopulmonary Bypass trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04296071, a study of Cardiopulmonary Bypass and Lung Injury, is actively recruiting participants, sponsored by Sophia Koutsogiannaki.

RECRUITING
Registry status
56 participants
Enrollment target
1
Study location

Study Summary

Acute lung injury (ALI) following cardiopulmonary bypass (CPB) is a serious complication, often prolonging the length of stay in ICU and potentially dealing to mortality. The objective of this study is to assess the mechanism of CPB-mediated acute lung injury in pediatric patients.

Interventions

  • OTHER Research study

Study Locations (1)

Massachusetts

  • Boston Children's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2022-10-14
Est. Completion 2026-12

Sponsor

Sophia Koutsogiannaki

1 total trials

What the Registry Record Tells You About NCT04296071

The ClinicalTrials.gov registry entry for NCT04296071 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 738-participant average among 9 other Cardiopulmonary Bypass trials with a reported enrollment target (92% lower). The listed sponsor is Sophia Koutsogiannaki, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cardiopulmonary Bypass appearing as the primary indexed condition, and to 1 intervention - of which Research study is the first listed.

NCT04296071 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04296071 about?

NCT04296071 is a clinical study titled "Neutrophil Phenotypic Profiling and Acute Lung Injury in Patients After Cardiopulmonary Bypass (CPB)". Acute lung injury (ALI) following cardiopulmonary bypass (CPB) is a serious complication, often prolonging the length of stay in ICU and potentially dealing to mortality. The objective of this study is to assess the mechanism of CPB-mediated acute lung injury in pediatric patients.

What is the current status of trial NCT04296071?

This trial is currently recruiting. The enrollment target is 56 participants. The study started on 2022-10-14. Estimated completion is 2026-12.

What conditions does trial NCT04296071 study?

This clinical trial studies the following conditions: Cardiopulmonary Bypass, Lung Injury.

What interventions are being tested in trial NCT04296071?

The interventions under investigation include: Research study (OTHER).

Who is sponsoring clinical trial NCT04296071?

This trial is sponsored by Sophia Koutsogiannaki, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04296071 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiopulmonary Bypass

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.